Semaglutide Injection Sites | Safety & Anatomical Guide

Last reviewed: May 16, 2026 Last updated: May 16, 2026

Written by: Jay Hastings , CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Compounded semaglutide is administered via subcutaneous injection into specific anatomical sites: the abdomen, thigh, or upper arm. Rotating injection sites across these regions helps reduce lipohypertrophy and local tissue reactions while maintaining consistent medication absorption.

Safe injection technique is foundational to treatment success, yet individual factors—including skin thickness, body composition, and genetic predispositions affecting inflammatory responses—can influence site selection and tolerance. Understanding these variables supports more personalized, evidence-based dosing conversations with your healthcare provider.

Approved Subcutaneous Injection Sites for Semaglutide

Compounded semaglutide may be injected into three primary anatomical regions: the abdomen (2 inches from the navel), anterior or lateral thigh, or upper arm (back of the arm between shoulder and elbow). Each site offers reliable subcutaneous absorption via the loose connective tissue layer beneath the skin.

Abdominal injections are most common due to consistent subcutaneous depth and patient comfort. Thigh and upper arm sites provide practical alternatives, particularly for patients with high abdominal adiposity or those who prefer rotation patterns. Systematic site rotation prevents local complications and maintains medication efficacy across treatment duration.

Site Rotation Strategies and Anatomical Considerations

Site rotation—changing injection location at each dose—reduces lipohypertrophy risk and maintains consistent insulin-like absorption kinetics. A structured rotation protocol might involve using the abdomen for 4 weeks, then switching to thigh, then upper arm, before returning to abdomen with a different anatomical location.

Understanding subcutaneous anatomy is critical: injecting too shallow (intradermal) or too deep (intramuscular) alters drug absorption. A 45-degree needle angle (4–6 mm needle) into the looser subcutaneous tissue layer ensures consistent depot formation and bioavailability.

Injection Site	Subcutaneous Depth	Absorption Profile	Rotation Frequency
Abdomen	Variable (2–4 cm)	Most consistent; faster onset	Rotate weekly or biweekly within region
Anterolateral Thigh	1.5–2.5 cm	Reliable; slightly slower onset	Rotate between left/right; avoid same spot
Upper Arm (posterior)	1–2 cm	Consistent; may delay onset slightly	Rotate shoulders between doses
Avoid Areas	Varies by location	Increased lipohypertrophy/bruising risk	Never inject same spot within 4 weeks

Local Tissue Response and Lipohypertrophy Prevention

Lipohypertrophy—abnormal fat tissue accumulation—occurs when repeated injections at the same site trigger local inflammation and adipocyte proliferation. Systematic rotation reduces this risk significantly. Studies show patients who rotate sites at intervals set by your prescriber, commonly about every 4 weeks maintain more uniform subcutaneous tissue quality and avoid tender injection sites.

Injection site reactions (redness, swelling, itching) are common but usually resolve within 24–48 hours. Persistent reactions may signal improper injection depth, repeated use of the same site, or rarely, a hypersensitivity response. Inform your provider if reactions intensify or if you notice induration or discoloration that doesn't resolve within one week.

Medical Screening and Individual Factors Affecting Site Selection

The PlexusDx Precision Peptide Genetic Test analyzes GIPR, FTO, and MC4R — variants that relate to GLP-1 and related signaling pathways. It does not predict your response to semaglutide or determine your dose; it offers pathway-level context for a conversation with your provider. Genetics is a guide, not a guarantee.

Body composition, age, and inflammatory phenotype influence local tissue response. Patients with inflammatory conditions, obesity-related lipohypertrophy, or those on concurrent anti-inflammatory medications may experience different local reactions. Provider guidance on site selection and technique adjustment supports optimal safety and comfort.

How PlexusDx Supports a More Personalized Approach

PlexusDx's Precision Peptide Genetic Test may help provide context on inflammatory pathway predispositions (including markers related to tissue response and wound healing) that could influence injection site tolerance and local reaction patterns. This information should be interpreted alongside clinical assessment by a qualified healthcare provider.

Genetic variants in inflammatory response genes may correlate with heightened injection site reactions or altered lipohypertrophy risk in some individuals. While the Precision Peptide Genetic Test does not predict exact semaglutide response, it reveals predispositions in peptide metabolic and inflammatory pathways that can support a more informed provider conversation about site selection and monitoring.

Understanding your genetic predispositions for inflammatory response can help guide a more personalized injection site rotation plan and adverse event monitoring strategy with your provider. This data-informed approach supports safer, more comfortable long-term compounded semaglutide therapy.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection is $289/mo month-to-month, or from $249/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $298 to personalize your protocol from day one.

Frequently Asked Questions

Which body regions does this guide identify for compounded semaglutide?

Three: the abdomen, the thigh, and the upper arm. The article describes the abdomen as most common because subcutaneous depth is consistent there, with the anterolateral thigh and the back of the upper arm offered as alternatives, particularly for people with high abdominal adiposity. Anyone administering medication should follow the directions from their prescriber and the product labeling.

What is lipohypertrophy, and why does the article keep returning to it?

The post defines it as abnormal fat tissue accumulation that develops when repeated injections in the same spot trigger local inflammation and adipocyte proliferation. It is the main risk the article uses to justify systematic site rotation, and it says people who vary the location every one to two weeks maintain more uniform subcutaneous tissue quality and avoid tender areas.

How does the article's table compare absorption across the three regions?

It lists the abdomen with a variable subcutaneous depth of 2 to 4 cm and the most consistent, fastest onset; the anterolateral thigh at 1.5 to 2.5 cm with reliable but slightly slower onset; and the posterior upper arm at 1 to 2 cm, consistent but possibly slightly delayed. A fourth row covers areas to avoid because of raised lipohypertrophy and bruising risk.

Which local reactions does the post consider normal versus worth reporting?

It calls redness, swelling, and itching common and says they usually settle within 24 to 48 hours. Persistent reactions, by contrast, may point to improper depth, repeated use of one spot, or rarely a hypersensitivity response. The article says to inform your provider if reactions intensify, or if induration or discoloration does not clear within a week.

Which patient factors does the article say can change local tissue response?

It names body composition, age, and inflammatory phenotype, and singles out people with inflammatory conditions, obesity-related lipohypertrophy, or those taking anti-inflammatory medications as likely to see different local reactions. Its conclusion is that site selection and technique adjustments should come from provider guidance rather than one rule applied to everyone.

Related Reading

• Injection Semaglutide
• Compounded Semaglutide 2
• Mounjaro Injection Sites
• Injection Sites For Ozempic

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. References are included at the end of the article when scientific, medical, or health-related claims are discussed.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.